by Bevin Fletcher for Bioscience Technology: There is an urgent need to ramp up the number of therapies entering the Alzheimer’s disease pipeline, according the Cleveland Clinic’s second annual analysis of Alzheimer’s disease drug development. If changes aren’t made, the……
‘Desperately Slow’ Period in Alzheimer’s Drug Development
by Bevin Fletcher for Bioscience Technology: There is an urgent need to ramp up the number of therapies entering the Alzheimer’s disease pipeline, according the Cleveland Clinic’s second annual analysis of Alzheimer’s disease drug development. If changes aren’t made, the……